Jiangsu Yabang Epson Pharmaceutical Co Ltd.

Healthy Chinese subjects were used as test subjects. A self-crossover design was used to determine the time course of olopatadine concentration in plasma after administration of olopatadine hydrochloride tablets produced under license by Jiangsu Yabang Epson Pharmaceutical Co., Ltd., and to estimate the corresponding pharmacokinetic parameters. Olopatadine hydrochloride tablets [trade name: Allelock®, specification: 5 mg] produced under license by Kyowa Kirin Co., Ltd. were used as reference to evaluate the bioequivalence between the preparations and to observe the safety of olopatadine hydrochloride tablets in healthy Chinese subjects.

The main purpose of the study was to use the Telmisartan Tablets (Specification: 80 mg) developed by Jiangsu Yabang Epson Pharmaceutical Co., Ltd. as the test preparation and the Telmisartan Tablets (trade name: Micardis®/Micardis®, Specification: 80 mg) certified by Boehringer Ingelheim International GmbH as the reference preparation to study the pharmacokinetic parameters of the test preparation and the reference preparation after administration under fasting and high-fat meal conditions, and to evaluate the bioequivalence in humans. The secondary purpose of the study was to observe the safety of the test preparation and the reference preparation in healthy subjects.

The main purpose of the study: Using the difenidol hydrochloride tablets (specification: 25 mg) developed by Jiangsu Yabang Epson Pharmaceutical Co., Ltd. as the test preparation, according to the relevant provisions of the bioequivalence study, the pharmacokinetic characteristics of the difenidol hydrochloride tablets (reference preparation, trade name: Cephadol®, specification: 25 mg) produced by Japan Shinyaku Co., Ltd. were compared in healthy humans to investigate the bioequivalence of the two preparations. Secondary purpose of the study: To investigate the safety of the test preparation of difenidol hydrochloride tablets (specification: 25 mg) and the reference preparation (trade name: Cephadol®, specification: 25 mg) in healthy subjects.